Fortrea Holdings (MEX:FTRE1) Gross-Profit-to-Asset % : 13.77% (As of Mar. 2025)

View and export this data going back to 2023. Start your Free Trial

What is Fortrea Holdings Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Fortrea Holdings's annualized Gross Profit for the quarter that ended in Mar. 2025 was MXN9,534 Mil. Fortrea Holdings's average Total Assets over the quarter that ended in Mar. 2025 was MXN69,249 Mil. Therefore, Fortrea Holdings's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2025 was 13.77%.

Fortrea Holdings Gross-Profit-to-Asset % Historical Data

The historical data trend for Fortrea Holdings's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fortrea Holdings Gross-Profit-to-Asset % Chart

Fortrea Holdings Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Gross-Profit-to-Asset %

13.83

16.31

12.76

15.04

Fortrea Holdings Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Gross-Profit-to-Asset %	Get a 7-Day Free Trial									9.95	14.81	16.99	16.02	13.77

Competitive Comparison of Fortrea Holdings's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Fortrea Holdings's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fortrea Holdings's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fortrea Holdings's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Fortrea Holdings's Gross-Profit-to-Asset % falls into.

Save Embed

;

Save Embed

;

Fortrea Holdings Gross-Profit-to-Asset % Calculation

Fortrea Holdings's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2024 )	/	( (Total Assets (A: Dec. 2023 )	+	Total Assets (A: Dec. 2024 ))	/ count )
	=	11141.115	/	( (73542.627	+	74646.721)	/ 2 )
	=	11141.115	/	74094.674
	=	15.04 %

Fortrea Holdings's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2025 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Mar. 2025 )	/	( (Total Assets (Q: Dec. 2024 )	+	Total Assets (Q: Mar. 2025 ))	/ count )
	=	9533.52	/	( (74646.721	+	63852.088)	/ 2 )
	=	9533.52	/	69249.4045
	=	13.77 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2025) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Fortrea Holdings Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Fortrea Holdings's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Fortrea Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fortrea Holdings Inc (MEX:FTRE1) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

FTRE:USA K67:Germany

Address

8 Moore Drive, Durham, NC, USA, 27709

Website

https://www.fortrea.com

Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.

Fortrea Holdings Headlines

No Headlines